Abstract：
Alveolar echinococcosis (AE) is a zoonotic parasitic disease, resulting from being infected with the metacestode larvae of the tapeworm Echinococcus multilocularis (E. multilocularis). Novel prophylactic and therapeutic interventions are urgently needed since the current chemotherapy displays limited efficiency in AE treatment. Bioengineered nano cellular membrane vesicles are widely used for displaying the native conformational epitope peptides because of their unique structure and biocompatibility. In this study, four T-cells and four B-cells dominant epitope peptides of E. multilocularis with high immunogenicity were engineered into the Vero cell surface to construct a membrane vesicle nanovaccine for the treatment of AE. The results showed that the nanovesicle vaccine can efficiently activate dendritic cells, induce specific T/B cells to form a mutually activated circuit, and inhibit E. multilocularis infection. This study presents for the first time a nanovaccine strategy that can completely eliminate the burden of E. multilocularis.
摘要：
肺泡包虫病(AE)是一种人畜共患寄生虫病,由于感染了多房棘球蚴的后生幼虫。由于目前的化疗在AE治疗中显示出有限的效率，因此迫切需要新的预防和治疗干预措施。生物工程纳米细胞膜囊泡因其独特的结构和生物相容性而被广泛用于展示天然构象表位。在这项研究中,将具有高免疫原性的多房大肠杆菌的四个T细胞和四个B细胞优势表位肽工程化到Vero细胞表面，以构建用于治疗AE的膜囊泡纳米疫苗。结果表明,纳米囊泡疫苗能高效激活树突状细胞,诱导特异性T/B细胞形成相互激活的回路，并抑制多房性大肠杆菌感染。这项研究首次提出了一种纳米疫苗策略，可以完全消除多房性大肠杆菌的负担。
